Press release
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven
About this update from Jyong Biotech Ltd.
[{"type":"text","content":"New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that the Company has entered into a non‑binding letter of intent (the “LOI”) with a South Korean pharmaceutical company to review and evaluate the potential in‑licensing and development of Jyong Biotech’s plant-derived new drug MCS-2for the Korean market. The prospective partner is a recognized supplier to both general hospitals and clinics, and the LOI reflects mutual interest in assessing commercial and regulatory pathways for introducing MCS products in Korea. This engagement is consistent with Jyong Biotech’s co‑commercialization strategy to collaborate with regional partners that offer established sales networks and local regulatory expertise. Definitive terms are being negotiated between the parties and the partnership, if such definitive terms will be agreed upon, would aim to leverage the partner’s commercial infrastructure to accelerate market access and patient reach in Korea. The LOI is non‑exclusive and subject to customary due diligence, regulatory review, negotiation of definitive agreements, and other closing conditions. Fu Feng Kuo, Chairwoman of Jyong Biotech, commented: “A selective co‑commercialization approach with strategic partners will enable broader and faster patient access by combining its product development capabilities with partners’ commercial scale and local market knowledge. The Company will work to advance LOI negotiation with these strategic partners and provide updates as material developments occur.” As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments. About Jyong Biotech Ltd. Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new...